Small Molecule Innovator CDMO Market Trends, Segments, Demand 2024-2033 | Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, Evonik Industries AG, Lonza Group Ltd., Labcorp Drug Development

The Small Molecule Innovator CDMO Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Small Molecule Innovator CDMO Market:

https://www.thebusinessresearchcompany.com/report/small-molecule-innovator-cdmo-global-market-report

According to The Business Research Company’s Small Molecule Innovator CDMO Global Market Report 2024, The small molecule innovator cdmo market size has grown strongly in recent years. It will grow from $51.84 billion in 2023 to $56.13 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising demand for outsourcing, increasing complexity of small molecule drugs, increasing focus on time-to-market, cost pressures on pharma companies, stringent regulatory requirements.

The small molecule innovator cdmo market size is expected to see strong growth in the next few years. It will grow to $76.46 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to rise in personalized medicine and targeted therapies, increased focus on green chemistry and sustainability, demand for faster time-to-market for new drugs, expansion of biopharmaceutical pipeline, emergence of advanced therapies. Major trends in the forecast period include rise of virtual and remote development models, increased collaboration and partnerships in the pharma industry, expansion of cdmo services to emerging markets, utilization of single-use technologies in manufacturing, evolution of cdmos into strategic development partners.

The rising prevalence of chronic diseases is expected to propel the growth of the small-molecule innovator CDMO market going forward. Chronic diseases are diseases that last a year or longer, necessitating continuing medical care, restricting everyday activities, or both. Small molecule innovator CDMO provides services and manufactures chronic disease medicines for pharmaceutical and biotech companies. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that in the US by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising from 71.522 million in 2020 to 142.66 million. Therefore, the rising prevalence of chronic diseases is propelling the small-molecule innovator CDMO market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12178&type=smp

The small molecule innovator cdmo market covered in this report is segmented –

1) By Product: Small Molecule Active Pharmaceutical Ingredient(API), Small Molecule Drug Product

2) By Stage: Preclinical, Clinical, Commercial

3) By Therapeutic: Cardiovascular Disease, Oncology, Respiratory Disorders, Neurology, Metabolic Disorders, Infectious Disease, Other Therapeutics

4) By Customer: Pharmaceutical, Biotechnology

Product innovations are a key trend gaining popularity in the small molecule CDMO market. Major companies operating in the small-molecule innovator CDMO market are adopting new innovative products to sustain their position in the market. For instance, in May 2023, Oxford Biomedica, a UK-based company, launched TetraVecta, the next-generation system for CDMO. Small-molecule innovator enterprises can overcome prior difficulties in medicinal development due to the payload’s size, complexity, or interference to be delivered. Furthermore, the TetraVecta technology helps accelerate the development and implementation of in vivo gene treatments.

The small molecule innovator cdmo market report table of contents includes: